Exploring the components of bleeding outcomes in transfusion trials for patients with hematologic malignancy
- 13 October 2020
- journal article
- research article
- Published by Wiley in Transfusion
- Vol. 61 (1) , 286-293
Abstract
Background: Clinically significant bleeding in patients with hematologic malignancies is a heterogeneous composite outcome currently defined as World Health Organization (WHO) bleeding Grades 2, 3, and 4. However, the clinical significance of some minor bleeds categorized as WHO Grades 1 and 2 remains controversial. We analyzed the number and frequency of individual signs and symptoms of WHO Grades 1 and 2 bleeds and explored their association with more severe incident bleeds graded as WHO Grades 3 and 4.Study Design and Methods: We aggregated daily bleeding assessment data from three randomized controlled trials conducted in patients with hematologic malignancies that used bleeding as an outcome. Cox proportional hazard regression analysis was used to identify signs and symptoms categorized as WHO Grades 1 and 2 bleeds that were associated with more severe bleeds (Grades 3 and 4).Results: We collected data from 315 patients (n = 5476 daily bleeding assessments; 3383 [61.8%] with a bleed documented). A total of 98.3% (3326/3383) were Grade 1 and 2 bleeds and 1.7% (57/3383) were Grades 3 and 4. Grade 1 and 2 bleeds were composed of 20 different bleeding signs and symptoms. Hematuria (hazard ratio, 16.1; 95% confidence interval, 4.4‐59.2; P < .0001) was associated with incident Grade 3 or 4 bleeds.Conclusion: In patients with hematologic malignancy, only hematuria (microscopic and/or macroscopic) was associated with more severe incident bleeds. This findings require validation in independent data sets.Keywords
Funding Information
- Canadian Blood Services (Program Support Award 2017)
This publication has 16 references indexed in Scilit:
- Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysisHaematologica, 2015
- Adjudicating bleeding events in a platelet dose study: impact on outcome results and challengesTransfusion, 2011
- Time to rethink clinically important outcomes in platelet transfusion trialsTransfusion, 2010
- Composite outcomes in clinical trials: what are they and when should they be used?Transfusion, 2010
- Dose of Prophylactic Platelet Transfusions and Prevention of HemorrhageNew England Journal of Medicine, 2010
- A randomized controlled trial comparing standard- and low-dose strategies for transfusion of platelets (SToP) to patients with thrombocytopeniaBlood, 2009
- A multicenter pilot‐randomized controlled trial of the feasibility of an augmented red blood cell transfusion strategy for patients treated with induction chemotherapy for acute leukemia or stem cell transplantationTransfusion, 2007
- Methodologic issues in the use of bleeding as an outcome in transfusion medicine studiesTransfusion, 2003
- The Threshold for Prophylactic Platelet Transfusions in Adults with Acute Myeloid LeukemiaNew England Journal of Medicine, 1997
- Acute leukaemia and malignant lymphoma patients'experiences of disease, treatment and nursing care during the active treatment phase: an explorative studyEuropean Journal of Cancer Care, 1995